Literature DB >> 1967461

Use of diphosphonates in hypercalcaemia due to malignancy.

J A Kanis, E V McCloskey, A H Paterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1967461

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 2.  Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Authors:  A J Coukell; A Markham
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 3.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 4.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.

Authors:  S J Wimalawansa; R D Gunasekera
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

6.  [Pamidronate in the treatment of tumor-associated hypercalcemia].

Authors:  M Pecherstorfer; S Janisch; C Marosi; C Wogritsch; C Bosse; W Schratzberger; E Gerber; A Fortelny; R Lenzhofer; H Rainer
Journal:  Klin Wochenschr       Date:  1991-10-02

7.  A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers.

Authors:  Gianluigi Poli; Fabrizia Mariotti; Mario Ermanno Corrado; Daniela Acerbi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

Review 8.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

9.  Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?

Authors:  S Shah; Janet Hardy; E Rees; J Ling; B Gwilliam; C Davis; K Broadley; R A'Hern
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.

Authors:  N P O'Rourke; E V McCloskey; S Vasikaran; K Eyres; D Fern; J A Kanis
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.